EGFR FISH Assay for Lung Cancer Treatment
Author Information
Author(s): Marileila Varella-Garcia
Primary Institution: University of Colorado Health Sciences Center
Hypothesis
The EGFR gene copy number determined by FISH can predict clinical outcomes for NSCLC patients treated with EGFR TKIs.
Conclusion
The EGFR FISH assay can effectively stratify NSCLC patients for treatment with EGFR-TKIs based on gene copy number.
Supporting Evidence
- EGFR gene copy number is a significant predictor of response to EGFR TKIs.
- Patients with high EGFR copy numbers showed better clinical outcomes.
- FISH assay results correlate with survival rates in NSCLC patients treated with gefitinib.
Takeaway
Doctors can use a special test to see if lung cancer patients will benefit from certain medicines by checking their genes.
Methodology
The study utilized the EGFR FISH assay to analyze gene copy numbers in NSCLC patients.
Potential Biases
Potential biases may arise from the retrospective nature of some studies referenced.
Limitations
The study acknowledges the need for further prospective clinical trials to validate the findings.
Participant Demographics
The study included over 6,000 patients with advanced non-small cell lung cancer.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website